After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a
session left, it looks less likely the sector ends in the black for the year.
The following are catalysts that could dictate the moves of biotech stocks in the unfolding week.
Conferences
Goldman Sachs 11th Annual Healthcare CEOs Unscripted: A View From The Top is Jan. 3 in New York City.
PDUFA Dates
The FDA is set to announce its verdict on the prior approval supplement, or PAS, submitted by Portola Pharmaceuticals
Inc (NASDAQ: PTLA) for its anticoagulant antidote
drug Andexxa, which was approved May 3. The application for PAS pertains to a large-scale Generation 2 manufacturing
process for Andexxa. The D-day is Dec. 31.
Clinical Trials
Sesen Bio Inc (NASDAQ: SESN) on Jan. 3
will release six-month data from a late-stage study of Vicinium, its investigational candidate for non-muscle invasive bladder
cancer.
Pending Q4, Year-End Releases
Some of the releases scheduled for the above period are yet to be reported. Click
here for pipeline candidates, the indications for which each is they're being evaluated and the type of data due.
Related Links:
6
Valuable Pipeline Drugs With Upcoming Catalysts
FDA Warms To
Considering Legal Cannabis Ingredients In Food
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.